Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Procaps Group SA

Procaps Group SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.07
  • Today's Change0.39 / 23.21%
  • Shares traded32.25k
  • 1 Year change-43.44%
  • Beta0.1504
Data delayed at least 15 minutes, as of Sep 23 2024 18:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

  • Revenue in USD (TTM)414.10m
  • Net income in USD52.20m
  • Incorporated2021
  • Employees5.50k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Elutia Inc24.99m-70.10m136.24m54.00------5.45-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Eton Pharmaceuticals Inc31.38m-6.69m140.03m30.00--10.37--4.46-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Hongchang International Co Ltd4.65m-292.22k140.08m8.00--3.57--30.13-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Lifecore Biomedical Inc128.26m9.33m154.49m524.0033.7413.518.491.200.14820.23183.831.760.50552.144.26244,774.803.68-5.914.35-8.3332.6331.017.27-19.161.060.23730.6923--24.20-25.46114.5334.47-16.72--
Biostem Technologies Inc131.44m7.87m166.13m67.0030.489.1720.551.260.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Procaps Group SA414.10m52.20m189.54m5.50k3.234.812.720.45770.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Mediwound Ltd20.14m-19.97m189.63m100.00--9.14--9.41-2.16-2.162.181.920.33115.536.55201,410.00-32.83-24.48-49.28-32.9213.2543.27-99.17-38.431.51-3.260.2623---29.4840.6065.73--64.66--
ASP Isotopes Inc2.30m-27.05m190.72m76.00--13.54--83.08-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Scilex Holding Co50.83m-171.53m191.79m113.00------3.77-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Greenwich Lifesciences Inc0.00-10.22m195.59m3.00--33.09-----0.7942-0.79420.000.44960.00----0.00-112.41-36.43-123.67-38.31------------0.00-------13.63------
Amylyx Pharmaceuticals Inc298.76m-165.87m211.06m384.00--0.8077--0.7064-2.45-2.454.343.840.76053.6915.91778,026.10-42.22---50.91--84.64---55.52--4.66--0.00--1,612.94--124.84------
Telomir Pharmaceuticals Inc0.00-18.74m232.14m1.00--148.09-----0.6855-0.68550.000.05290.00----0.00-467.16---686.91-------------0.92990.00-------1,430.39------
Inhibrx Biosciences Inc1.85m1.63bn235.67m166.000.13431.070.144127.18121.21121.210.043415.150.0079--4.8611,162.65693.63-77.06815.31-93.91----88,264.55-1,590.91---21.960.00---17.88-26.85-66.20--26.30--
Rigel Pharmaceuticals Inc130.30m-14.23m242.11m147.00------1.86-0.8136-0.81367.45-1.701.061.055.24886,401.40-11.59-28.82-19.93-47.2692.4197.88-10.92-35.761.48-1.732.00---2.7921.3057.16--68.45--
Data as of Sep 23 2024. Currency figures normalised to Procaps Group SA's reporting currency: US Dollar USD

Institutional shareholders

0.37%Per cent of shares held by top holders
HolderShares% Held
Credicorp Capital Asset Management SA AGFas of 31 Dec 2023256.41k0.23%
Lemanik Asset Management SAas of 30 Jun 2023101.57k0.09%
Geode Capital Management LLCas of 30 Jun 202428.94k0.03%
Citadel Securities LLCas of 31 Mar 202412.50k0.01%
SSgA Funds Management, Inc.as of 31 Mar 202412.36k0.01%
Activest Wealth Management LLCas of 30 Jun 202410.00k0.01%
RBC Dominion Securities, Inc.as of 31 Mar 2024362.000.00%
Pineridge Advisors LLCas of 30 Jun 2024250.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024100.000.00%
UBS Securities LLCas of 31 Mar 202442.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.